Oncology Pharma Stock Performance
| ONPH Stock | USD 0 0.00 0.00% |
Oncology Pharma holds a performance score of 17 on a scale of zero to a hundred. The company holds a Beta of 14.93, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oncology Pharma will likely underperform. Use Oncology Pharma jensen alpha, as well as the relationship between the value at risk and skewness , to analyze future returns on Oncology Pharma.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Oncology Pharma are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Oncology Pharma demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Oncology |
Oncology Pharma Relative Risk vs. Return Landscape
If you would invest 0.06 in Oncology Pharma on October 13, 2025 and sell it today you would earn a total of 0.34 from holding Oncology Pharma or generate 566.67% return on investment over 90 days. Oncology Pharma is currently generating 41.8813% in daily expected returns and assumes 185.2295% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Oncology, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oncology Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncology Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Oncology Pharma, and traders can use it to determine the average amount a Oncology Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2261
| High Returns | Best Equity | ONPH | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Oncology Pharma is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncology Pharma by adding it to a well-diversified portfolio.
Oncology Pharma Fundamentals Growth
Oncology Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Oncology Pharma, and Oncology Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncology Pink Sheet performance.
| Profit Margin | 18.21 % | |||
| Operating Margin | (1.42) % | |||
| Current Valuation | 756.68 K | |||
| Shares Outstanding | 1.16 M | |||
| Price To Sales | 66.28 X | |||
| Revenue | 10.21 K | |||
| EBITDA | (8.65 K) | |||
| Cash And Equivalents | 3.21 K | |||
| Total Debt | 205.9 K | |||
| Cash Flow From Operations | 7.06 K | |||
| Total Asset | 198.59 K | |||
About Oncology Pharma Performance
By evaluating Oncology Pharma's fundamental ratios, stakeholders can gain valuable insights into Oncology Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oncology Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncology Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California. Oncology Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Oncology Pharma performance evaluation
Checking the ongoing alerts about Oncology Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Oncology Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncology Pharma is way too risky over 90 days horizon | |
| Oncology Pharma has some characteristics of a very speculative penny stock | |
| Oncology Pharma appears to be risky and price may revert if volatility continues | |
| Oncology Pharma currently holds 205.9 K in liabilities. Oncology Pharma has a current ratio of 0.86, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncology Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Oncology Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncology Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncology to invest in growth at high rates of return. When we think about Oncology Pharma's use of debt, we should always consider it together with cash and equity. |
- Analyzing Oncology Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncology Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Oncology Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncology Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncology Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncology Pharma's pink sheet. These opinions can provide insight into Oncology Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Oncology Pink Sheet analysis
When running Oncology Pharma's price analysis, check to measure Oncology Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Pharma is operating at the current time. Most of Oncology Pharma's value examination focuses on studying past and present price action to predict the probability of Oncology Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Pharma's price. Additionally, you may evaluate how the addition of Oncology Pharma to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |